Cantor Fitzgerald Reaffirms Overweight Rating for Celldex Therapeutics (NASDAQ:CLDX)

Cantor Fitzgerald reiterated their overweight rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a research report sent to investors on Monday, Benzinga reports. The brokerage currently has a $67.00 target price on the biopharmaceutical company’s stock.

CLDX has been the topic of several other research reports. Wolfe Research initiated coverage on Celldex Therapeutics in a research report on Tuesday, June 11th. They set an outperform rating and a $51.00 price target on the stock. HC Wainwright reaffirmed a buy rating and issued a $80.00 target price on shares of Celldex Therapeutics in a report on Monday, August 12th. Stifel Nicolaus initiated coverage on shares of Celldex Therapeutics in a research report on Tuesday, June 18th. They issued a buy rating and a $58.00 price target for the company. Finally, Wells Fargo & Company raised their price objective on shares of Celldex Therapeutics from $35.00 to $37.00 and gave the stock an equal weight rating in a research report on Monday, August 12th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus price target of $63.83.

Celldex Therapeutics Stock Performance

Shares of NASDAQ CLDX opened at $41.16 on Monday. The firm has a market capitalization of $2.71 billion, a PE ratio of -14.44 and a beta of 1.56. Celldex Therapeutics has a fifty-two week low of $22.11 and a fifty-two week high of $53.18. The stock’s 50-day simple moving average is $38.51 and its 200-day simple moving average is $38.80.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.05. Celldex Therapeutics had a negative net margin of 1,809.18% and a negative return on equity of 23.66%. The company had revenue of $2.50 million during the quarter, compared to the consensus estimate of $1.13 million. On average, sell-side analysts forecast that Celldex Therapeutics will post -2.5 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Celldex Therapeutics

Several hedge funds have recently modified their holdings of CLDX. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Celldex Therapeutics in the second quarter valued at about $76,000. Headlands Technologies LLC purchased a new position in shares of Celldex Therapeutics during the 1st quarter worth approximately $147,000. CANADA LIFE ASSURANCE Co lifted its holdings in shares of Celldex Therapeutics by 26.4% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock valued at $192,000 after buying an additional 955 shares during the period. Aigen Investment Management LP purchased a new stake in shares of Celldex Therapeutics in the fourth quarter valued at approximately $251,000. Finally, Ameritas Investment Partners Inc. grew its holdings in Celldex Therapeutics by 34.3% during the first quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock worth $260,000 after acquiring an additional 1,582 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.